摘要
目的观察坎地沙坦酯联合阿托伐他汀治疗高血压病合并阵发性房颤(paroxysmal atrial fibrillation,PAF)的疗效及治疗前后超敏C反应蛋白(hs-CRP)、白细胞介素-18(IL-18)、N端脑钠肽前体(NT-proBNP)、左心房内径(LAD)及血压的变化。方法选取2019年1月至2020年2月郑州大学第一附属医院心血管内科一病区收治的高血压病合并PAF 80例患者,将服用坎地沙坦酯片治疗的40例作为对照组,将在对照组基础上加服阿托伐他汀钙片治疗的40例作为治疗组,连续治疗6个月。观察两组治疗前后的临床疗效、血压、维持窦性心律情况、hs-CRP、IL-18、NT-proBNP及LAD大小的变化情况。结果治疗后,对照组有效率为77.50%,治疗组则为95.00%,其差异有统计学意义(P<0.05);治疗前两组收缩压和舒张压比较差异无统计学意义(P>0.05),治疗组治疗后收缩压和舒张压均低于对照组(P<0.05);治疗组治疗后3个月和6个月窦性心律维持的例数均高于对照组(P<0.05);治疗前两组hs-CRP、IL-18、NT-proBNP及LAD比较差异无统计学意义(P>0.05),治疗后两组均降低,且治疗组hs-CRP、IL-18、NT-proBNP及LAD均低于对照组(P<0.05)。结论坎地沙坦酯联合阿托伐他汀治疗高血压病合并PAF疗效确切,其机制可能与炎症反应有关。
Objective To observe the effect of Candesartan ester combined with atorvastatin in the treatment of hypertensive patients with paroxysmal atrial fibrillation(PAF),to observe the changes of hypersensitive C-reactive protein(hs-CRP),interleukin-18(IL-18),NT-proBNP,left atrial diameter(LAD)and blood pressure before and after treatment.Methods Atotal of 80 patients with hypertension combined with PAF admitted to the First Department of Cardiovascular Medicine of the First Affiliated Hospital of Zhengzhou University from January 2019 to February 2020 were selected.40 pa-tients treated with Candesartan ester tablets were selected as the control group,and 40 patients treated with atorvastatin calci-um tablets on the basis of the control group were selected as the treatment group for 6 months.The clinical efficacy,blood pressure,sinus rhythm maintenance,hs-CRP,IL-18,NT-proBNP and LAD size of the two groups were observed before and after treatmen.Results After treatment,the effective rate was 77.50%in control group and 95.00%in treatment group,the difference was statistically significant(P<0.05).There was no significant difference in systolic and diastolic blood pres-sure between the two groups before treatment(P>0.05),and the systolic and diastolic blood pressure in the treatment group were lower than those in the control group after treatment(P<0.05).The number of sinus rhythm maintenance cases in the treatment group at 3 months and 6 months after treatment was higher than that in the control group(P<0.05).There was no significant difference in hs-CRP,IL-18,NT-proBNP and LAD between the two groups before treatment(P>0.05),and after treatment,the hs-CRP,IL-18,NT-proBNP and LAD in the treatment group were lower than those in the control with atorvastatin is effective in the treatment of hypertensive patients with PAF,and its mechanism may be related to inflammation.
作者
王晓玲
刘宇宙
邬海燕
冯方方
皇甫梅梅
WANG Xiao-ling;LIU Yu-Zhou;WU Hai-yan;FENG Fang-Fang;HUANG Fu Mei-mei(Department of Cardiovascular Medicine,the First Affiliated Hospital of Zhengzhou University,Zhengzhou 450052,China)
出处
《医药论坛杂志》
2023年第11期76-79,共4页
Journal of Medical Forum
关键词
坎地沙坦酯
阿托伐他汀
高血压
阵发性房颤
Candesartan ester
Atorvastatin
Hypertensive
Paroxysmal atrial fibrillation
